Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07695974 | Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma | completed | — | 1,113 | University of Roma La SapienzaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06958601 | Safety and Efficacy of Transoral Robotic Thyroidectomy Versus Traditional Open Thyroidectomy for Thyroid Cancer | completed | — | 430 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER |
| 1 |
| Jul 9, 2026 |
| clinicaltrials |
| NCT07545837 | Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | recruiting | N/A | 20 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT03085056 | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | active not recruiting | Early Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT03345563 | Project HERO: Health Empowerment & Recovery Outcomes(HERO) | completed | N/A | 113 | Rutgers, The State University of New JerseyOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04238624 | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT01813136 | Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma | completed | Phase 2 | 168 | Centre Leon BerardOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04000880 | Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health(AMPLIFY) | completed | N/A | 603 | University of Alabama at BirminghamOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT02185560 | Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib(JPMS-DTC) | active not recruiting | — | 453 | BayerINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04892303 | Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer | recruiting | Phase 1 | 48 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02856347 | Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin(CMTpostopFDOPA) | completed | N/A | 24 | Institut Claudius RegaudOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06959641 | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer | recruiting | Phase 2 | 33 | Jochen LorchOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03285230 | The French E3N Prospective Cohort Study(E3N) | active not recruiting | — | 100,000 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04290663 | Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up(INTERMEDIATE) | recruiting | Phase 3 | 368 | Centre Francois BaclesseOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06790706 | IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers(IMMUNORARE5) | active not recruiting | Phase 2 | 27 | Hospices Civils de LyonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07529080 | Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA Trial | not yet recruiting | N/A | 142 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07659717 | Frozen Section-Guided Selective Ipsilateral Central Neck Dissection in Bethesda V-VI Thyroid Nodules | completed | — | 66 | Eleonora Lori, MDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT06007924 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07661420 | 211At-MABG in Adults With Advanced Neuroendocrine Cancers | not yet recruiting | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06961084 | Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer | recruiting | Phase 2 | 62 | Thomas HopeOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05172921 | Environmental Factors and Thyroid Cancer | recruiting | — | 500 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07654322 | Clinical Study on the Efficacy of Laparoscopic Assisted Open Surgery Through Subclavian Approach for Unilateral Thyroid Cancer | not yet recruiting | — | 400 | Xijing HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT07600580 | The Association Between Bilateral Intermediate Cervical Plexus Block During Total Thyroidectomy and Surgical Stress Response | recruiting | Phase 4 | 48 | University Hospital DubravaOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT02747888 | Hereditary Risk Factors for Thyroid Cancer | recruiting | N/A | 250 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07506161 | Radiofrequency Ablation Treatment of Low-Risk Papillary Thyroid Carcinomas | completed | — | 27 | Premier G Med Cardio KftINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07634978 | Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients | recruiting | N/A | 150 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03196518 | Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer | active not recruiting | N/A | 5 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT07628543 | Computer Vision-Based Recognition of Parathyroid Glands and Recurrent Laryngeal Nerves in Endoscopic Surgery(PTAIR) | not yet recruiting | — | 100 | Fujian Medical UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630363 | PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC | not yet recruiting | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04566393 | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | available | — | — | xCuresINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07623005 | Progressive Muscle Relaxation for Pain and Quality of Life in Thyroid Cancer(PMRT-ThyCa) | completed | N/A | 32 | University of FaisalabadOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07621146 | A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies(NET-COMPARE) | not yet recruiting | — | 51 | British Columbia Cancer AgencyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07068542 | Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer | recruiting | N/A | 94 | Zhejiang Provincial People's HospitalOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT07584447 | Clinical Utility of Preoperative Thyroid GuidePx® Testing | not yet recruiting | — | 85 | University of CalgaryOTHER | 0 | Jun 1, 2026 | clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT06465017 | ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer | terminated | N/A | 149 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07612293 | STAGE-MTC Trial Thyroid Lobectomy With Ipsilateral Central Neck Dissection | not yet recruiting | N/A | 100 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04589624 | An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy | recruiting | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04759911 | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07376837 | Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study(PTC-RFA) | recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT01552434 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | terminated | Phase 1 | 154 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT00510640 | Thyroid Cancer and Sunitinib(THYSU) | completed | Phase 2 | 71 | University Hospital, BordeauxOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT01947023 | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | May 14, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2026source: clinicaltrials